Vaccination and the evolutionary ecology of human papillomavirus

Vaccine

Volumn 26, Issue SUPPL. 3, 2008, Pages

  Poolman, Eric M ^a   Elbasha, Elamin H ^b   Galvani, Alison P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Evolution; Human papillomavirus; Vaccine

Indexed keywords

ARTICLE; ECOLOGY; IMMUNE RESPONSE; MATHEMATICAL MODEL; PRIORITY JOURNAL; VACCINATION; VERRUCA VULGARIS; VIRUS TRANSMISSION; WART VIRUS;

ADOLESCENT; CHILD; ECOSYSTEM; EVOLUTION; HUMANS; MODELS, BIOLOGICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 46249113882     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.04.010     Document Type: Article

References (36)

1. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87 11 (1995) 796-802
2. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
3. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
4. Munoz N., Bosch F.X., Castellsague X., Diaz M., de Sanjose S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 2 (2004) 278-285
5. Lehtinen M., and Paavonen J. Vaccination against human papillomaviruses shows great promise. Lancet 364 9447 (2004) 1731-1732
6. Steinbrook R. The potential of human papillomavirus vaccines. N Engl J Med 354 11 (2006) 1109-1112
7. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., and Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 3 5 (2006) e138
8. Dunne E., Unger E., Sternberg M., McQuillan G., Swan D., Patel S., et al. Prevalence of HPV infection among females in the United States. JAMA 297 8 (2007) 813-819
9. Franco E.L., Villa L.L., Sobrinho J.P., Prado J.M., Rousseau M.C., Desy M., et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180 5 (1999) 1415-1423
10. Christensen N.D., and Kreider J.W. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol 64 7 (1990) 3151-3156
11. Roden R.B., Hubbert N.L., Kirnbauer R., Christensen N.D., Lowy D.R., and Schiller J.T. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 70 5 (1996) 3298-3301
12. Kawana K., Yasugi T., Kanda T., Kino N., Oda K., Okada S., et al. Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 21 27-30 (2003) 4256-4260
13. Pastrana D.V., Gambhira R., Buck C.B., Pang Y.Y., Thompson C.D., Culp T.D., et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337 2 (2005) 365-372
14. Ho G.Y., Studentsov Y., Hall C.B., Bierman R., Beardsley L., Lempa M., et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 186 6 (2002) 737-742
15. Rousseau M.C., Pereira J.S., Prado J.C., Villa L.L., Rohan T.E., and Franco E.L. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 184 12 (2001) 1508-1517
16. Thomas K.K., Hughes J.P., Kuypers J.M., Kiviat N.B., Lee S.K., Adam D.E., et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 182 4 (2000) 1097-1102
17. Mendez F., Munoz N., Posso H., Molano M., Moreno V., van den Brule A.J., et al. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 192 7 (2005) 1158-1165
18. Elbasha E.H., and Galvani A.P. Vaccination against multiple HPV types. Math Biosci 197 1 (2005) 88-117
19. Halpern A.L. Comparison of papillomavirus and immunodeficiency virus evolutionary patterns in the context of a papillomavirus vaccine. J Clin Virol 19 1-2 (2000) 43-56
20. Hutchinson G.E. Concluding remarks. Cold Spring Harbor Symposium on Quantitative Biology (1957) 415-427
21. Gause G.F. The Struggle for Existence (1934), Williams & Wilkins, Baltimore
22. Goldie S.J., Grima D., Kohli M., Wright T.C., Weinstein M., and Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 106 6 (2003) 896-904
23. Hogewoning C.J., Bleeker M.C., van den Brule A.J., Voorhorst F.J., Snijders P.J., Berkhof J., et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 107 5 (2003) 811-816
24. Hughes J.P., Garnett G.P., and Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 13 6 (2002) 631-639
25. Laumann E.O. The Social Organization of Sexuality: Sexual Practices in the United States. (1994), University of Chicago Press, Chicago
26. Richardson H., Kelsall G., Tellier P., Voyer H., Abrahamowicz M., Ferenczy A., et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12 6 (2003) 485-490
27. Rousseau M.C., Villa L.L., Costa M.C., Abrahamowicz M., Rohan T.E., and Franco E. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex Transm Dis 30 7 (2003) 581-587
28. Chaturvedi A.K., Myers L., Hammons A.F., Clark R.A., Dunlap K., Kissinger P.J., et al. Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections. Cancer Epidemiol Biomarkers Prev 14 10 (2005) 2439-2445
29. Sasagawa T., Yamazaki H., Dong Y.Z., Satake S., Tateno M., and Inoue M. Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. Int J Cancer 75 4 (1998) 529-535
30. Wideroff L., Schiffman M., Haderer P., Armstrong A., Greer C.E., Manos M.M., et al. Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions. J Infect Dis 180 5 (1999) 1424-1428
31. Combita A.L., Bravo M.M., Touze A., Orozco O., and Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer. Int J Cancer 97 6 (2002) 796-803
32. Liaw K.L., Hildesheim A., Burk R.D., Gravitt P., Wacholder S., Manos M.M., et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 183 1 (2001) 8-15
33. Kjaer S.K., Munk C., Winther J.F., Jorgensen H.O., Meijer C.J., and van den Brule A.J. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 14 6 (2005) 1528-1533
34. Fraser C., Tomassini J.E., Xi L., Golm G., Watson M., Giuliano A.R., et al. Modeling the long-termantibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25 21 (2007) 4324-4333
35. Pinto L.A., Viscidi R., Harro C.D., Kemp T.J., Garcia-Pineres A.J., Trivett M., et al. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology (2006)
36. Emeny R.T., Wheeler C.M., Jansen K.U., Hunt W.C., Fu T.M., Smith J.F., et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol 76 15 (2002) 7832-7842